Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2013, Article ID 424915, 6 pages
http://dx.doi.org/10.1155/2013/424915
Review Article

Bimodal Solutions or Twice-Daily Icodextrin to Enhance Ultrafiltration in Peritoneal Dialysis Patients

1Hemodialysis Unit, Kyanous Stavros Patras, Germanou 115, 26225 Patras, Greece
2Peritoneal Dialysis Program, University Health Network, University of Toronto, ON, Canada

Received 15 August 2012; Accepted 18 December 2012

Academic Editor: Wai-Kei Lo

Copyright © 2013 Periklis Dousdampanis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. G. Blake, “Icodextrin: fifteen years and counting,” Peritoneal Dialysis International, vol. 29, no. 4, pp. 367–369, 2009. View at Google Scholar · View at Scopus
  2. D. S. Davies, “Kinetcs of icodextrin,” Peritoneal Dialysis International, vol. 14, supplement 2, pp. S45–S50, 1994. View at Google Scholar
  3. J. Plum, S. Gentile, C. Verger et al., “Metabolic and laboratory effect of icodextrin,” American Journal of Kidney Diseases, vol. 39, no. 4, pp. 862–871, 2002. View at Google Scholar
  4. F. Finkelstein, H. Healy, A. Abu-Alfa et al., “Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration,” Journal of the American Society of Nephrology, vol. 16, no. 2, pp. 546–554, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. C. J. A. M. Konings, J. P. Kooman, M. Schonck et al., “Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study,” Kidney International, vol. 63, no. 4, pp. 1556–1563, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. M. E. Wilkie, M. J. Plant, L. Edwards, and C. B. Brown, “Icodextrin 7.5% dialysate solution (Glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival,” Peritoneal Dialysis International, vol. 17, no. 1, pp. 84–87, 1997. View at Google Scholar · View at Scopus
  7. K. Honda, K. Nitta, S. Horita et al., “Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration,” Nephrology Dialysis Transplantation, vol. 14, no. 6, pp. 1541–1549, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Freida, B. Issad, M. Dratwa et al., “A combined crystalloid and colloid Pd solution as a glucose-sparing strategy for volume control in high-transport Apd Patients: a prospective multicenter study,” Peritoneal Dialysis International, vol. 29, no. 4, pp. 433–442, 2009. View at Google Scholar · View at Scopus
  9. J. Gobin, S. Fernando, S. Santacroce, and F. O. Finkelstein, “The utility of two daytime icodextrin exchanges to reduce dextrose exposure in automated peritoneal dialysis patients: a pilot study of nine patients,” Blood Purification, vol. 26, no. 3, pp. 279–283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Sav, O. Oymak, M. T. Inanc, A. Dogan, B. Tokgoz, and C. Utas, “Effects of twice-daily icodextrin administration on blood pressure and left ventricular mass in patients on continuous ambulatory peritoneal dialysis,” Peritoneal Dialysis International, vol. 29, no. 4, pp. 443–449, 2009. View at Google Scholar · View at Scopus
  11. P. Dousdampanis, K. Trigka, M. Chu et al., “Two icodextrin exchanges per day in peritoneal dialysis patients with ultrafiltration failure: one center's experience and review of the literature,” International Urology and Nephrology, vol. 43, no. 1, pp. 203–209, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Ballout, E. Garcia-Lopez, J. Struyven, C. Marechal, and E. Goffin, “Double-dose icodextrin to increase ultrafiltration in pd patients with inadequate ultrafiltration,” Peritoneal Dialysis International, vol. 31, no. 1, pp. 91–94, 2011. View at Google Scholar
  13. M. C. Brown, K. Simpson, J. J. Kerssens, and R. A. Mactier, “Encapsulating peritoneal sclerosis in the new millennium: a national cohort study,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 7, pp. 1222–1229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. R. M. Alsop, “History, chemical and pharmaceutical development of icodextrin,” Peritoneal Dialysis International, vol. 14, supplement 2, pp. S5–S12, 1994. View at Google Scholar
  15. J. B. Moberly, S. Mujais, T. Gehr et al., “Pharmacokinetics of icodextrin in peritoneal dialysis patients,” Kidney International, Supplement, vol. 62, no. 81, pp. S23–S33, 2002. View at Google Scholar · View at Scopus
  16. J. M. Young and E. Weser, “The metabolism of circulating maltose in man,” Journal of Clinical Investigation, vol. 50, no. 5, pp. 986–991, 1971. View at Google Scholar · View at Scopus
  17. C. D. Mistry, R. Gokal, and E. Peers, “A randomized multicenter clinical trial comparing isosmolar icodextrin with hyper-osmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peitoneal Dialysis,” Kidney International, vol. 46, no. 2, pp. 496–503, 1994. View at Google Scholar
  18. E. García-López, B. Anderstam, O. Heimbürger, G. Amici, A. Werynski, and B. Lindholm, “Determination of high and low molecular weight molecules of icodextrin in plasma and dialysate, using gel filtration chromatography, in peritoneal dialysis patients,” Peritoneal Dialysis International, vol. 25, no. 2, pp. 181–191, 2005. View at Google Scholar · View at Scopus
  19. J. Plum, S. Gentile, C. Verger et al., “Efficacy and safety of a 7.5% Icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis,” American Journal of Kidney Diseases, vol. 39, no. 4, pp. 862–871, 2002. View at Google Scholar · View at Scopus
  20. K. Ota, T. Akiba, T. Nakao et al., “Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5% icodextrin solution in Japanese patients,” Peritoneal Dialysis International, vol. 23, no. 4, pp. 356–361, 2003. View at Google Scholar · View at Scopus
  21. A. W. de Boer, C. H. Schröder, R. van Vliet, J. L. Willems, and L. A. H. Monnens, “Clinical experience with icodextrin in children: ultrafiltration profiles and metabolism,” Pediatric Nephrology, vol. 15, no. 1-2, pp. 21–24, 2000. View at Google Scholar · View at Scopus
  22. A. Rodríguez-Carmona, M. Pérez-Fontán, E. García López, T. García Falcón, and H. Díaz Cambre, “Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study,” Peritoneal Dialysis International, vol. 27, no. 3, pp. 260–266, 2007. View at Google Scholar · View at Scopus
  23. N. Posthuma, P. M. Ter Wee, A. J. M. Donker et al., “Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell,” Peritoneal Dialysis International, vol. 17, no. 6, pp. 602–607, 1997. View at Google Scholar · View at Scopus
  24. E. Garcia-Lopez, B. Lindholm, and A. Tranaeus, “Biocompatibility of new peritoneal solutions: clinical experience,” Peritoneal Dialysis International, vol. 20, supplement 5, pp. S48–S54, 2000. View at Google Scholar
  25. J. Perl, S. J. Nessim, and J. M. Bargman, “The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both,” Kidney International, vol. 79, no. 8, pp. 814–824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Witowski, J. Wisniewska, K. Korybalska et al., “Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells,” Journal of the American Society of Nephrology, vol. 12, no. 11, pp. 2434–2441, 2001. View at Google Scholar · View at Scopus
  27. A. S. Charonis, L. A. Reger, J. E. Dege et al., “Laminin alterations after in vitro nonenzymatic glycosylation,” Diabetes, vol. 39, no. 7, pp. 807–814, 1990. View at Google Scholar · View at Scopus
  28. N. Posthuma, P. M. Ter Wee, A. J. M. Donker, P. L. Oe, E. M. Peers, and H. A. Verbrugh, “Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis,” Peritoneal Dialysis International, vol. 20, supplement 2, pp. S106–S113, 2000. View at Google Scholar · View at Scopus
  29. S. J. Davies, E. A. Brown, N. E. Frandsen et al., “Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription,” Kidney International, vol. 67, no. 4, pp. 1609–1615, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. M. A. Bajo, R. Selgas, M. A. Castro et al., “Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo,” Peritoneal Dialysis International, vol. 20, no. 6, pp. 742–747, 2001. View at Google Scholar · View at Scopus
  31. A. Parikova, M. M. Zweers, D. G. Struijk, and R. T. Krediet, “Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions,” Advances in Peritoneal Dialysis, vol. 19, pp. 186–190, 2003. View at Google Scholar · View at Scopus
  32. M. Moriishi and H. Kawanishi, “Icodextrin and intraperitoneal inflammation,” Peritoneal Dialysis International, vol. 28, supplement 3, pp. S96–S100, 2008. View at Google Scholar · View at Scopus
  33. M. Moriishi, H. Kawanishi, H. Watanabe, and S. Tsuchiya, “Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane,” Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis, vol. 21, pp. 21–24, 2005. View at Google Scholar · View at Scopus
  34. G. Queffeulou, M. Bernard, F. Vrtovsnik et al., “Severe cutaneous hypersensitivity requiring permanent icodextrin withdrawal in a CAPD patient,” Clinical Nephrology, vol. 51, no. 3, pp. 184–186, 1999. View at Google Scholar · View at Scopus
  35. F. Touré, S. Lavaud, M. Mohajer et al., “Icodextrin-induced peritonitis: study of five cases and comparison with bacterial peritonitis,” Kidney International, vol. 65, no. 2, pp. 654–660, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. M. L. Lambie, B. John, L. Mushahar, C. Huckvale, and S. J. Davies, “The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made,” Kidney International, vol. 78, no. 6, pp. 611–618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. M. R. Korte, D. E. Sampimon, H. F. Lingsma et al., “Risk factors associated with encapsulating peritoneal sclerosis in DUTCH EPS Study,” Peritoneal Dialysis International, vol. 31, no. 3, pp. 269–278, 2011. View at Google Scholar
  38. R. T. Krediet, “Effects of icodextrin on the peritoneal membrane,” Nephrology Dialysis Transplantation, vol. 25, no. 5, pp. 1373–1375, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Woodrow, B. Oldroyd, G. Stables, J. Gibson, J. H. Turney, and A. M. Brownjohn, “Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis,” Nephrology Dialysis Transplantation, vol. 15, no. 6, pp. 862–866, 2000. View at Google Scholar · View at Scopus
  40. C. Fourtounas, A. Hardalias, P. Dousdampanis, B. Papachristopoulos, E. Savidaki, and J. G. Vlachojannis, “Sodium removal in peritoneal dialysis: the role of icodextrin and peritoneal dialysis modalities,” Advances in Peritoneal Dialysis, vol. 24, pp. 27–31, 2008. View at Google Scholar · View at Scopus
  41. R. Paniagua, M. D. J. Ventura, M. Ávila-Díaz et al., “Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients,” Peritoneal Dialysis International, vol. 29, no. 4, pp. 422–432, 2009. View at Google Scholar · View at Scopus
  42. S. B. Jenkins and M. E. Wilkie, “An exploratory study of a novel peritoneal combination dialysate (1.36% glucose/7.5% icodextrin), demonstrating improved ultrafiltration compared to either component studied alone,” Peritoneal Dialysis International, vol. 23, no. 5, pp. 475–480, 2003. View at Google Scholar · View at Scopus
  43. S. J. Davies, G. Woodrow, K. Donovan et al., “Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial,” Journal of the American Society of Nephrology, vol. 14, no. 9, pp. 2338–2344, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Perl and J. M. Bargman, “The importance of residual kidney function for patients on dialysis: a critical review,” American Journal of Kidney Diseases, vol. 53, no. 6, pp. 1068–1081, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Peers, “Icodextrin plus glucose combinations for use in CAPD,” Peritoneal Dialysis International, vol. 17, supplement 2, pp. S68–S69, 1997. View at Google Scholar · View at Scopus
  46. F. Dallas, S. B. Jenkins, and M. E. Wilkie, “Enhanced ultrafiltration using 7.5% icodextrin/1.36% glucose combination dialysate: a pilot study,” Peritoneal Dialysis International, vol. 24, no. 6, pp. 542–546, 2004. View at Google Scholar · View at Scopus
  47. P. Freida, M. Galach, J. C. Divino Filho, A. Werynski, and B. Lindholm, “Combination of crystalloid (glucose) and colloid (icodextrin) osmotic agents markedly enhances peritoneal fluid and solute transport during the long PD dwell,” Peritoneal Dialysis International, vol. 27, no. 3, pp. 267–276, 2007. View at Google Scholar · View at Scopus
  48. S. Davies, O. Carlsson, O. Simonsen et al., “The effects of low-sodium peritoneal dialysis fluids on blood pressure, thirst and volume status,” Nephrology Dialysis Transplantation, vol. 24, no. 5, pp. 1609–1617, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Galach, A. Werynski, J. Waniewski, P. Freida, and B. Lindholm, “Kinetic analysis of peritoneal fluid and solute transport with combination of glucose and icodextrin as osmotic agents,” Peritoneal Dialysis International, vol. 29, no. 1, pp. 72–80, 2009. View at Google Scholar · View at Scopus
  50. A. Akonour and J. K. Leypoldt, “Three-pore model predictions of 24- hour automated peritoneal dialysis therapy using bimodal solutions,” Peritoneal Dialysis International, vol. 31, no. 5, pp. 537–544, 2011. View at Google Scholar
  51. B. Rippe and L. Levin, “Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD,” Kidney International, vol. 57, no. 6, pp. 2546–2556, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. T. K. Jeloka, F. F. Ersoy, M. Yavuz et al., “What is the optimal dwell time for maximizing ultrafiltration with icodextrin exchange in automated peritoneal dialysis patients?” Peritoneal Dialysis International, vol. 26, no. 3, pp. 336–340, 2006. View at Google Scholar · View at Scopus
  53. T. Sav, M. T. Inanc, A. Dogan, O. Oymak, and C. Utas, “Two daytime icodextrin exchanges decrease brain natriuretic peptide levels and improve cardiac functions in continuous ambulatory peritoneal dialysis patients,” Nephrology, vol. 15, no. 3, pp. 307–312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. P. G. Blake, J. M. Bargman, K. S. Brimble et al., “Clinical practice guidelines and recommendations on peritoneal dialysis adequacy 2011,” Peritoneal Dialysis International, vol. 31, no. 2, pp. 218–239, 2011. View at Google Scholar